Here is the synopsis of our sample research paper on Hoechst-Roussel Pharmaceuticals Inc and RU 486. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
This 8 page paper examines the difficulties that Hoechst-Roussel Pharmaceuticals Inc faced when considering whether to introduce the contraceptive/abortion drug RU 486, also known as also known as mifepristone, into the United States. The paper looks at the issues to be considered in adding this to the existing product line. Factors included in the paper are ethical issues and moral responsibilities, commercial pressures, stakeholder approach and different ethical theories that may aid in the decision making process. The paper uses a source supplied by the student as the reference. The bibliography cites 1 source.
Page Count:
8 pages (~225 words per page)
File: TS14_TEru4861.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
for the increased markets that are being found with the drugs that create a greater options for treatment and make use of the extensive research and development that has taken
place. The decision whether or not to introduce RU 486 into the United States may be seen as one that was influenced not only by the direct commercial potential, but
constrained by the ethical considerations that would impact on the companys entire range as a result of consumer action. The launch of RU 486 was initially seen in 1988 in
France, but was nearly halted due to the action taken, not only against the product, but against the company and its other product lines. By looking at the companys environment,
the stakeholders and the ethical considerations the difficulty of the position which Hoechst-Roussel Pharmaceuticals Inc. found itself may be better appreciated. The
main purpose of any commercial enterprise may be seen as the satisfaction of the primary stakeholders; the shareholders. However, this becomes more complex when companies that produce goods which have
the power of life or death and concern health issues. Pharmaceutical companies must, by necessity, take a wider view, but this is not in conflict with models of corporate governance
such as Milton Friedmans shareholder wealth maximisation model. Other interests may be taken into account as long as they are a requirement to increase the return that is created for
the shareholder, but are not required where they do not enhance this singular value. Although many companies may argued that they are taking the more altruistic corporate wealth maximisation model
as their guide, where a stakeholder approach is central and profit is only one of many goals rather than a primary goal. However, buy looking at the Hoechst-Roussel Pharmaceuticals
...